Abstract

The Wistar Institute Cancer Center Director is Dr. Russel Kaufman. He is assisted by two Deputy Directors: Drs. Meenhard Herlyn and Frank J. Rauscher, III. Dr. Herlyn is the Deputy Director for Translational Research. In this newly created position, Dr. Herlyn will cultivate intra- and inter-programmatic translational collaborations within the Cancer Center, helping to ensure that the needs of the Cancer Center principal investigators are met. He also will share in the recruiting efforts for new members of the Cancer Center, and provide advice to the Director. Dr. Frank J. Rauscher III is the Deputy Director for Basic Research. He holds several important national positions that give him a perspective on the directions and opportunities in basic cancer research, enabling him to provide scientific guidance to the Cancer Center Director and take a leadership role with program leaders and Cancer Center members in basic research planning, recruitment, and development of infrastructure.

Public Health Relevance

Three very experienced cancer scientists and administrators with extensive national leadership experience head the Cancer Center, providing vision, perspective, and creative energy that will enhance the collaborations and effectiveness of the Cancer Center and make it an exciting, innovative environment for beginning scientists to start their careers.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-41
Application #
8102100
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
41
Fiscal Year
2010
Total Cost
$294,466
Indirect Cost

  Institution

Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Colón, Krystal; Speicher, David W; Smith, Peter et al. (2018) S100a14 is Increased in Activated Nk Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-Nk crosstalk. J Acquir Immune Defic Syndr :
Schug, Zachary T (2018) Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon ""Bi""-cycle. Biochemistry 57:889-890
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7
Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269

Showing the most recent 10 out of 741 publications